Structured evidence table for Astragalus Immune Function Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Astragalus Immune Function Randomized Trial | However, despite the increasing number of studies, current evidence on YPFS remains fragmented and lacks systematic integration. | 3 | Gao Shiyu (2026) | Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence |
| Astragalus Immune Function Randomized Trial | Further research by Huand Zhaosuggests that YPFS may influence biological processes, including tumor-associated angiogenesis and cell proliferation, by modulating multiple signaling pathways such as AGE-RAGE, IL-17, TNF, and MAPK. | 3 | Gao Shiyu (2026) | Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence |
| Astragalus Immune Function Randomized Trial | Compared with individual herbs, YPFS demonstrates superior efficacy in modulating Th1/Th2 and Th17/Treg balance, improving tumor-associated immunosuppressive microenvironments (eg., PD-1/PD-L1 and STAT3 signaling axes), and enhancing anti-infective capacity. | 3 | Gao Shiyu (2026) | Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence |
| Astragalus Immune Function Randomized Trial | 1 2 3 4 5 6–8 http://mpns.kew.org/ http://mpns.kew.org/ http://mpns.kew.org/ Dan xi Xin Fa Yupingfeng San (YPFS) is a classical traditional Chinese herbal formula (TCM prescription),composed of Astragalus mongholicus Bunge (Huang Qi) (January 22, 2026), Atractylodes macrocephala Koidz. | 3 | Gao Shiyu (2026) | Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence |
| Astragalus Immune Function Randomized Trial | 5 6 7 8 9 Aging is accompanied by a progressive decline in cellular and organ function, leading to an increased incidence of chronic diseases and neurodegenerative disorders. | 4 | Kanubaddi Kiran Reddy (2026) | Astragalus and Cordyceps Derivatives in the Treatment of Aging-Related Chronic Diseases and Neurodegenerative Disorders |
| Astragalus Immune Function Randomized Trial | These conditions frequently coexist, and many individuals over the age of 60 present with multiple comorbidities that require combination therapies, which can complicate treatment strategies and increase the risk of drug interactions [,]. | 4 | Kanubaddi Kiran Reddy (2026) | Astragalus and Cordyceps Derivatives in the Treatment of Aging-Related Chronic Diseases and Neurodegenerative Disorders |
| Astragalus Immune Function Randomized Trial | Astragalus Cordyceps 13 18 Althoughis a plant-derived medicine andis a fungus-derived medicine, both have been reported to regulate biological mechanisms closely associated with aging, including oxidative stress, chronic inflammation, mitochondrial dysfunction, metabolic imbalance, immune dysregulation, and neuroinflammatory injury [,]. | 4 | Kanubaddi Kiran Reddy (2026) | Astragalus and Cordyceps Derivatives in the Treatment of Aging-Related Chronic Diseases and Neurodegenerative Disorders |
| Astragalus Immune Function Randomized Trial | 1 2 3 4 Traditional Chinese herbal medicines have been widely used for centuries due to their long history, broad accessibility, and rich chemical diversity. | 4 | Kanubaddi Kiran Reddy (2026) | Astragalus and Cordyceps Derivatives in the Treatment of Aging-Related Chronic Diseases and Neurodegenerative Disorders |
Source documents